country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-U00224

Copy Link Print Information

BRL44385

BRL44385 is a potent and selective inhibitor of the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV2), varicella zoster virus (VZV) and Epstein-Barr virus (EBV).

For research use only. We do not sell to patients.

CAS No.: 114778-60-8
Formula: C₈H₁₁N₅O₃
Molecular Weight:225.20

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

BRL44385 Chemical Structure

CAS No.: 114778-60-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
Chemical Information
Protocol
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

BRL44385 is a potent and selective inhibitor of the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV2), varicella zoster virus (VZV) and Epstein-Barr virus (EBV).

IC₅₀ & Target^[1]

HSV-1

HSV-2

All HSV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MRC5	IC₅₀	0.71 μM Compound: 8, BRL-44385	Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells. Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells.	[PMID: 2153202]
MRC5	IC₅₀	4.4 μM Compound: 8, BRL-44385	Antiviral activity in plaque reduction assay was determined against varicella zoster virus (VZV) in MRC-5 cells. Antiviral activity in plaque reduction assay was determined against varicella zoster virus (VZV) in MRC-5 cells.	[PMID: 2153202]
Vero	IC₅₀	2.1 μM Compound: 8, BRL-44385	Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 1 (HSV-1) in Vero cells. Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 1 (HSV-1) in Vero cells.	[PMID: 2153202]

In Vivo

BRL44385 is a selective antiherpesvirus agent. Following oral administration, BRL 55792 is very well absorbed and provides high and prolonged concentrations of BRL44385 in the blood. In mice 15 min and 60 min after administration of a single oral dose of BRL 55792, the concentrations of BRL44385 in the blood are considerably higher than those obtain after oral administration of either BRL44385 or BRL46720 and the bioavailability of BRL 44385 from oral BRL 55792 is 66% of that achieves with the same dose of the sodium salt of BRL44385 administered intravenously^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 114778-60-8
Molecular Weight 225.20
Formula C₈H₁₁N₅O₃
SMILES

O=C1N=C(N)NC2=C1N=CN2OCCCO
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocol

Animal Administration^[1]

Mice^[1]
BRL44385 is administered as a single dose of 0.2 mmol/kg in 0.1 mL of 1% carboxymethylcellulose by oral gavage to female Balb/c mice weighing approximately 20 g. Food is withheld for 18 h prior to the start of the experiment. Blood is collected by cardiac puncture using heparinized syringes 15, 60, and 180 min after dosing. Equal volumes (0.2 mL) from three mice are pooled at each time point and 0.6 mL of 16% trichloroacetic acid is added. After centrifugation, 0.5 mL of supernatant is added to 0.1 mL of saturated aqueous NaHCO₃ followed by the addition of 0.6 mL of 0.4 mM NH₄OAc (pH 6.0) and the mixture analysed by HPLC.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. M. R. Harnden, et al. Synthesis, oral bioavailability and in vivo activity of acetal derivatives of the selective antiherpesvirus agent 9-(3-hydroxypropoxy) guanine (SRL 44385). Antiviral Chemistry & Chemotherapy (1994) 5(3), 147-154.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
Chemical Information
Protocol
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

BRL44385

All HSV Isoforms